2020
Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis
Das A, Mahapatra S, Bandyopadhyay D, Samanta S, Chakraborty S, Philpotts LL, Jahangir E, Roy B. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis. Critical Reviews In Oncology/Hematology 2020, 157: 103186. PMID: 33309571, DOI: 10.1016/j.critrevonc.2020.103186.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsHumansNetwork Meta-AnalysisProtein Kinase InhibitorsReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth FactorsConceptsTyrosine kinase inhibitorsHemorrhagic eventsVEGFR-TKICancer patientsOdds ratioVascular endothelial growth factor tyrosine kinase inhibitorVascular endothelial growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsKinase inhibitorsHigh-grade bleedingSide effect profileStandard chemotherapeutic regimenFirst-choice treatmentConfidence intervalsRandom-effects modelTypes of cancerVEGFR-TKIsChemotherapeutic regimenPrimary outcomeClinical trialsHigh riskPlaceboComparative riskPatients
2018
Comparison of treatment options for depression in heart failure: A network meta-analysis
Das A, Roy B, Schwarzer G, Silverman MG, Ziegler O, Bandyopadhyay D, Philpotts LL, Sinha S, Blumenthal JA, Das S. Comparison of treatment options for depression in heart failure: A network meta-analysis. Journal Of Psychiatric Research 2018, 108: 7-23. PMID: 30419488, DOI: 10.1016/j.jpsychires.2018.10.007.Peer-Reviewed Original ResearchConceptsHeart failure patientsStandardized mean differenceHF patientsFailure patientsClinical trialsDepressive symptomsConfidence intervalsRandom-effects modelPlacebo-controlled conditionsUsual standardWeb of ScienceUsual careHeart failurePrimary outcomeSuch patientsMeasures of depressionPoor outcomeTreatment optionsOvid MEDLINETherapeutic effectTherapeutic benefitElectronic searchPatientsMean differenceDifferent interventions